Market Performance - The new stock index and the near-term new stock index fell by 2.01% and 2.23% respectively during the first week of February 2026[7] - The market experienced significant adjustments, with the technology sector leading the decline, particularly in the non-ferrous metals and electronic sectors[7] New Stock Listings - The first unprofitable new stock of the year, Beixin Life, was listed, achieving an average first-day increase of 185.65%[1] - Two new stocks contributed to A1/A2/B class investors' single-account full returns of 17.80/9.44/7.90 thousand yuan, enhancing the yield rates for a 500 million yuan scale account by 0.36‰/0.19‰/0.16‰[41] Trading Activity - Trading activity in the new stock sector continued to decline, with turnover rates for the new stock index and near-term new stock index dropping by 2.10 percentage points and 2.25 percentage points respectively[21] - The net active selling in the new stock sector amounted to 2.936 billion yuan, a decrease of 3.540 billion yuan from the previous week[23] Valuation Changes - The new stock index PE (TTM) increased by 1.76, while the near-term new stock index PE (TTM) decreased by 23.73[14] - The latest PE (TTM) values for the new stock index and near-term new stock index were 80.0X and 159.7X, corresponding to historical percentile levels of 83.8% and 99.2% respectively[14]

IPO Pipeline Overview - As of February 8, there are 318 companies in the IPO pipeline, including 20 on the Shanghai Main Board, 41 on the Sci-Tech Innovation Board, 18 on the Shenzhen Main Board, 37 on the Growth Enterprise Market, and 202 on the Beijing Stock Exchange [1]. IPO Application Status - The IPO application status for the 318 companies includes 8 accepted, 227 under inquiry, 16 approved, 46 suspended, and 21 submitted for registration [2]. Newly Listed Companies - Two companies were newly listed between February 2 and February 8: - Shimen Supply Chain Management Co., Ltd. listed on February 3 with a closing price of 57.73 CNY per share, a 106.18% increase, and a trading volume of 1.093 billion CNY [4]. - Shenzhen Beixin Life Technology Co., Ltd. listed on February 5 with a closing price of 49.64 CNY per share, a 183.33% increase, and a trading volume of 1.409 billion CNY [4]. New Counseling Registrations - Fourteen companies received new counseling registrations during the same period, including: - Tianjin Sanying Precision Instrument Co., Ltd. focuses on high-end X-ray non-destructive testing equipment [6]. - Tianyi Space Technology Co., Ltd. is a leading operator of SAR satellite constellations [7]. - Guangdong Shenpeng Technology Co., Ltd. specializes in the development and production of brushless DC electronic water pumps [7]. - Hubei Chuda Intelligent Equipment Co., Ltd. provides glass forming equipment and intelligent system solutions [7]. Companies Approved for Review - Three companies successfully passed the review process: - Anhui Xinfeng New Energy Technology Co., Ltd. specializes in thermal management components for new energy vehicles [9]. - Guangdong Huahui Intelligent Equipment Co., Ltd. focuses on high-end intelligent equipment and key components [10]. - Shandong Chunguang Technology Group Co., Ltd. aims to become a world-class manufacturer of magnetic materials [11]. Companies Approved for Registration - Two companies received registration approval: - Wuhu Aiteke Automotive Electronics Co., Ltd. provides intelligent solutions for automotive electronics [12]. - Hangzhou Gaote Electronic Equipment Co., Ltd. specializes in battery management systems for the new energy industry [12]. Terminated IPO Applications - Wuxi Jiangsong Technology Co., Ltd. has withdrawn its IPO application during this period [14].

Core Viewpoint - North Chip Life (688712.SH) experienced a significant decline in stock price, closing at 44.83 yuan, down 5.74%, marking a new low since its listing on February 5, 2023 [1] Group 1: Company Overview - North Chip Life was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2023, with an issuance of 57 million shares, representing 13.67% of the total share capital post-issuance [1] - The initial offering price was set at 17.52 yuan per share [1] Group 2: Fundraising Details - The total amount raised from the issuance was 998.64 million yuan, with a net amount of 898.89 million yuan after deducting issuance costs [1] - The net fundraising amount was 53.32 million yuan less than the original plan of 952.21 million yuan [1] - The total issuance costs amounted to 99.75 million yuan, excluding VAT, with underwriting and sponsorship fees of 73.00 million yuan [1] Group 3: Future Plans - The funds raised are intended for the construction of an interventional medical device industrialization base, research and development projects for interventional medical devices, and to supplement working capital [1]

IPO Pipeline Overview - As of February 8, there are 318 companies in the IPO pipeline, with 20 on the Shanghai Main Board, 41 on the Sci-Tech Innovation Board, 18 on the Shenzhen Main Board, 37 on the Growth Enterprise Market, and 202 on the Beijing Stock Exchange [2] - The total number of companies at various stages includes 8 accepted, 227 under inquiry, 16 approved, 46 suspended, and 21 submitted for registration [3] Newly Listed Companies - Two companies were newly listed between February 2 and February 8: - Shimen Supply Chain Management Co., Ltd. listed on February 3 on the Shenzhen Main Board with stock code 001220, closing at 57.73 yuan per share, a rise of 106.18%, with a trading volume of 1.093 billion yuan and a turnover rate of 76.68% [5] - Shenzhen Beixin Life Technology Co., Ltd. listed on February 5 on the Sci-Tech Innovation Board with stock code 688712, closing at 49.64 yuan per share, a rise of 183.33%, with a trading volume of 1.409 billion yuan and a turnover rate of 75.88% [7] New Counseling Records - A total of 14 companies received new counseling records from February 2 to February 8, including: - Tianjin Sanying Precision Instrument Co., Ltd. focusing on high-end X-ray non-destructive testing equipment [9] - Tianyi Space Technology Co., Ltd. specializing in SAR satellite constellation operations [10] - Guangdong Shenpeng Technology Co., Ltd. engaged in the development and production of brushless DC electronic water pumps [10] Approval Status - Three companies successfully passed the review process from February 2 to February 8: - Anhui Xinfeng New Energy Technology Co., Ltd. focusing on thermal management components for new energy vehicles [14] - Guangdong Huahui Intelligent Equipment Co., Ltd. specializing in high-end intelligent equipment [14] - Shandong Chunguang Technology Group Co., Ltd. aiming to become a world-class manufacturer of magnetic materials [15] Registration Approval - Two companies received registration approval during the same period: - Wuhu Aiteke Automotive Electronics Co., Ltd. providing automotive electronic solutions [16] - Hangzhou Gaote Electronic Equipment Co., Ltd. focusing on battery management systems for the new energy sector [16] Termination of Review - Wuxi Jiangsong Technology Co., Ltd. withdrew its IPO application during the period, specializing in high-end intelligent equipment for photovoltaic cells [19]

Core Viewpoint - The successful listing of Beixin Life on the STAR Market marks a significant moment for domestic cardiovascular precision diagnostic device companies, highlighting the importance of global market access facilitated by Bluefan Medical, its largest overseas distributor [1][2]. Group 1: Company Overview - Beixin Life was listed at a price of 17.52 yuan per share, with its stock price surging over 200% on the first day, closing at 49.64 yuan, resulting in a market capitalization of nearly 20 billion yuan [1]. - Bluefan Medical has established itself as a key player in the global market for domestic medical devices, having built a unique channel for exporting innovative domestic products [1][2]. Group 2: Global Expansion Strategy - Bluefan Medical's acquisition of Baisheng International in 2018 allowed it to create a cardiovascular division, gaining access to a sales network covering over 100 countries and numerous international certifications [1][2]. - The company has developed a comprehensive platform for Chinese innovative medical devices, providing services such as global registration, clinical data support, and overseas sales network connections [2]. Group 3: Financial Performance - Beixin Life's overseas revenue saw a dramatic increase of 130.29% year-on-year in the first half of 2025, largely due to Bluefan Medical's channel support [2]. - Bluefan Medical's cardiovascular division achieved revenue exceeding 1.4 billion yuan in 2025, marking a growth of over 24% year-on-year and turning profitable [7]. Group 4: Product Development and Market Position - Bluefan Medical has established a full layout in the cardiovascular field, covering interventional cardiology, structural heart disease, neurointervention, and peripheral intervention, making it one of the few companies with comprehensive solutions in this area [4][5]. - The company has set up R&D centers in Germany, Singapore, and Shanghai, enabling it to respond effectively to market demands and enhance its competitive edge [3]. Group 5: Future Outlook - The listing of Beixin Life is seen as the beginning of a new logic for domestic medical device exports, emphasizing the need for effective market access and commercialization capabilities [7]. - Bluefan Medical is positioned as a "ferry operator" for domestic medical devices, facilitating the entry of innovative companies into global markets and potentially leading to a revaluation of its value as more partners join its export platform [7].

Group 1: IPO Overview - Zhuozheng Medical Holdings Limited (Zhuozheng Medical) was listed on the Hong Kong Stock Exchange on February 6, 2026, under the stock code "2677" [3] - The IPO raised a total of HKD 284 million by issuing 4,750,000 shares, with a subscription rate of 2730.73 times for the Hong Kong public offering and 5.79 times for the international offering [3] - Zhuozheng Medical's cornerstone investors include notable figures and companies such as He Xiaopeng, CEO of Xiaopeng Motors, and leading firms in the AI sector [4] Group 2: Company Performance - Zhuozheng Medical focuses on the high-end medical service market, targeting affluent consumers who prefer personalized healthcare [4] - The company ranked first and second among private high-end comprehensive medical service institutions in China based on the number of cities covered and patient visits projected for 2024 [4] - Revenue figures for Zhuozheng Medical from 2022 to 2024 are as follows: CNY 473 million, CNY 690 million, and CNY 959 million, with a compound annual growth rate (CAGR) of 42.2% [4] - Gross profit for the same period was CNY 44 million, CNY 134 million, and CNY 226 million, with a CAGR of 126.7% [4] - The company achieved profitability in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [4] Group 3: North Star Life - North Star Life Technology Co., Ltd. (North Star Life) was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2026, under the stock code "688712.SH" [6] - North Star Life specializes in innovative medical devices for cardiovascular disease diagnosis and treatment, having launched 11 products and having 6 in development as of September 30, 2025 [6][8] - The company's core products include the IVUS system and FFR system, both of which are recognized as leading innovations in China [7] Group 4: LuKe Technology - LuKe Technology (Beijing) Co., Ltd. (LuKe Technology) submitted its prospectus for listing on the Hong Kong Stock Exchange on February 6, 2026 [10] - Established in 2014, LuKe Technology focuses on smart locks and home security solutions, leading the market in China with a 5.8% share in 2024 [11] - The company reported revenues of CNY 1.015 billion in 2023 and CNY 1.086 billion in 2024, with a projected increase in revenue for the first three quarters of 2025 [11] Group 5: Tianyi Space Technology - Tianyi Space Technology Co., Ltd. (Tianyi Research Institute) signed a counseling agreement to initiate its A-share IPO process on January 27, 2026 [14] - The company has successfully launched 38 satellites, filling a gap in China's commercial SAR satellite market [15] - Tianyi's services include high-quality SAR data for various applications, contributing to disaster prevention and infrastructure monitoring [15] Group 6: BoRuiKang Technology - BoRuiKang Technology (Shanghai) Co., Ltd. (BoRuiKang) initiated its IPO process on the Sci-Tech Innovation Board on February 4, 2026 [18] - The company specializes in brain-machine interface technology and has successfully conducted surgeries using its product, NEO, in multiple hospitals [19] - BoRuiKang has received significant investments from various venture capital firms and aims to enhance its product capabilities in future iterations [19]

Summary of Key Points Core Viewpoint - The A-share IPO market is active with three companies approved for listing, while the Hong Kong IPO market continues to thrive, particularly in the innovative drug and high-end manufacturing sectors, with several key players making significant moves [2][6]. Group 1: A-share IPO Approvals - Three companies received approval for IPOs this week: Guangdong Huahui Intelligent Equipment Co., Ltd., Anhui Xinfeng New Energy Technology Co., Ltd., and Shandong Chunguang Technology Group Co., Ltd. [2][3][4]. - Huahui Intelligent focuses on high-end intelligent equipment and has seen rapid revenue growth, projecting over 4.2 billion yuan in revenue for 2024 and over 620 million yuan in net profit [3]. - Xinfeng Technology specializes in thermal management components for electric vehicles, with projected revenues of 6 billion yuan in 2024 and 13.81 billion yuan in 2025 [4][5]. - Chunguang Group leads in the production of soft magnetic ferrite powder, with revenues of 10.15 billion yuan in 2022 and a planned fundraising of 7.51 billion yuan for its IPO [5]. Group 2: Hong Kong IPO Market Activity - The Hong Kong IPO market welcomed five new listings, including four companies and one on the Sci-Tech Innovation Board, covering diverse sectors such as chemical new materials and cardiovascular medical devices [6][7]. - Guoen Technology debuted on the Hong Kong Stock Exchange, raising approximately 1 billion HKD, with plans for expansion in Thailand and domestic production [6]. - Beixin Life, the first medical device company listed on the Sci-Tech Innovation Board, saw its stock price surge by 183.33% on its first day, focusing on cardiovascular intervention devices [7]. - Leading companies in the PCB equipment sector, such as Dazhu CNC, raised significant funds for expansion into Southeast Asia, while Zhuozheng Medical and Muyuan Foods had mixed performances post-listing [8]. Group 3: Upcoming IPOs and Market Trends - The Hong Kong IPO market continues to be driven by hard technology, with companies like Danuo Pharmaceutical and Xian Dao Intelligent preparing for their listings, focusing on innovative drugs and lithium battery equipment [9][10]. - Danuo Pharmaceutical is set to raise funds for global clinical advancements, with its core product showing promising clinical data [9]. - Xian Dao Intelligent aims to raise 41.66 billion HKD, with a significant projected profit increase of 424% by 2025, expanding its services beyond lithium battery equipment [10]. - Wolong Nuclear Materials is also preparing for an IPO, focusing on new materials and global capacity expansion, with a fundraising target of up to 27.34 billion HKD [11].

Company Overview - Beixin Life, a leading company in the domestic cardiovascular precision interventional diagnosis and treatment field, officially listed on the Sci-Tech Innovation Board on February 5 [2] - Yifeng Capital, an early investor in Beixin Life since 2020, views the listing as a milestone in its investment layout in the biopharmaceutical and high-tech medical device sectors [2] Investment Motivation - Beixin Life is the first domestic medical device company with a product portfolio that includes intravascular functional FFR and imaging IVUS [3] - The investment was driven by the desire to break the international monopoly in the cardiovascular interventional field, where domestic alternatives were still in the "deep water zone" for high-end active devices [3] - The company aims to create an "intelligent cardiovascular precision interventional diagnosis and treatment system," providing more precise decision support for clinical applications, aligning with Yifeng Capital's investment principle of addressing unmet clinical needs [3] Industry Trends - The investment trend in the biopharmaceutical and medical device sectors has shifted from "following" to "running alongside," with a focus on "source innovation" in high-end medical devices [4] - Early-stage investments, particularly in preclinical or clinical phase I, are becoming increasingly important as mature asset valuations are high, making early positioning beneficial for cost control [4] - China's innovation is transitioning from "Fast-follow" to "First-in-class," emphasizing the need for early intervention to capture disruptive technologies [4] IPO Policies and Exit Strategies - Ongoing reforms in capital markets, such as the Sci-Tech Innovation Board and Hong Kong's 18A, are facilitating the listing of unprofitable tech companies, which is significant for early-stage investment firms like Yifeng Capital [5] - The diversification of exit strategies, including IPOs, cross-border collaborations, mergers and acquisitions, and secondary share transfers, provides more flexible return options and reduces early investment risks [5] - Investors are increasingly rational in their valuation judgments, focusing on true clinical value and differentiated advantages rather than merely the number of product pipelines, which will drive the industry back to its innovative essence [5] Future Outlook - The investment landscape in hard technology and biomedicine is characterized by long cycles and high risks, prompting a call for a focus on "patient capital" and deep engagement in specific sectors [6] - The emphasis is on teams with a composite background of "scientists + industrialization," possessing both top scientific insight and understanding of product development and commercialization [6] - Yifeng Capital aims to act as a bridge between technology and industry, assisting companies in navigating the "last mile" from the laboratory to the market [6]

Core Viewpoint - North Chip Life Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking the first successful listing of an innovative medical device company under the "fifth set of standards" [1][2] Company Overview - North Chip Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [1][3] - The company was founded in December 2015 by Song Liang, who has over 18 years of experience in advanced medical imaging technology and cardiovascular interventional device development [2][3] Financial Performance - The company has experienced significant revenue growth, with projected revenues of 520 million to 560 million yuan in 2025, representing a year-on-year increase of 64.24% to 76.88% [5] - The net profit for 2025 is expected to be between 78 million and 88 million yuan, marking a turnaround from previous losses [5] - The company raised a total of 999 million yuan in its IPO, with a net amount of 899 million yuan allocated primarily for the construction of an interventional medical device industrial base and R&D [5] Product Development and Market Position - North Chip Life has launched 11 products to the market and has 6 products in development, with its core IVUS and FFR systems having received special review and approval from national authorities [3][4] - The IVUS system is the first domestically approved 60MHz high-speed IVUS product and has captured a significant market share, while the FFR system holds a 30.6% share of the domestic market [4][5] R&D Investment - The company has consistently increased its R&D investment, totaling 389 million yuan over the past three years, with a workforce of 100 R&D personnel, over 40% of whom hold advanced degrees [3][5] Market Trends and Growth Potential - The domestic market for IVUS is expected to grow significantly, with projections indicating a compound annual growth rate of approximately 19.4% from 2024 to 2030 [8] - The overall market for precision-guided percutaneous coronary intervention (PCI) is anticipated to grow from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, with IVUS and FFR systems expected to dominate this market [8] Competitive Landscape - North Chip Life faces competition from established international firms and other domestic manufacturers in the IVUS and FFR markets, which may impact its market share and pricing strategies [7][8] - The company is also subject to pressures from national procurement policies that could affect pricing and market dynamics [7][8]

Core Viewpoint - North Chip Life Technology Co., Ltd. successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone in its mission to improve life and health through innovation and quality [1][8]. Company Overview - Established in December 2015 and headquartered in Shenzhen, North Chip Life is a national high-tech enterprise focused on the research, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [7][15]. - The company has been recognized as a national high-tech enterprise in 2018 and as a national-level specialized and innovative "little giant" enterprise in 2023 [7][15]. - North Chip Life has developed a complete chain for the independent research, production, and commercialization of high-end active interventional devices and consumables, achieving breakthroughs in domestic production processes and establishing an international quality system [7][15]. Market Performance - The IPO was sponsored by China International Capital Corporation, with an initial offering price of 17.52 yuan, which saw a 193% increase at opening and later surged by 396.58% to reach 87 yuan [3][10]. - As of the latest report, the stock price was 49.58 yuan, reflecting a 182.99% increase, with a total market capitalization of 20.7 billion yuan [3][10]. Industry Focus - North Chip Life specializes in the field of precise interventional diagnosis and treatment of cardiovascular diseases, which is characterized by a broad patient base, continuous clinical demand, and active technological innovation [5][13]. - The next decade is seen as a historic opportunity for the global medical device industry to accelerate towards intelligent and precise iterations, aligning with North Chip Life's vision of becoming a world-class medical technology enterprise with lasting influence [5][13]. Product Development - The company has obtained over 20 domestic and international Class III medical device registration certificates and has launched more than ten products, with several dozen more in development [7][15]. - Notable commercialized products include the first domestically innovative 60MHz high-definition intravascular ultrasound (IVUS) system and the first domestic flow reserve fraction (FFR) system approved by the NMPA [7][15]. - The company's pulse field ablation (PFA) system is the first PFA product in China to be included in the European Heart Rhythm Association's breakthrough clinical research progress, with clinical results published in the top cardiovascular journal JACC [8][16]. Global Reach - North Chip Life's core products are used in hospitals across 30 provinces in China and have been clinically applied in over 1,000 hospitals in more than ten countries, including Belgium, Germany, and Italy [8][16].